Adjuvant effects of a sequence-engineered mRNA vaccine: Translational profiling demonstrates similar human and murine innate response

Journal of Translational Medicine

Volumn 15, Issue 1, 2017, Pages

  Edwards, Darin K ^a   Jasny, Edith ^b   Yoon, Heesik ^a   Horscroft, Nigel ^b   Schanen, Brian ^a   Geter, Tanya ^a   Fotin Mleczek, Mariola ^b   Petsch, Benjamin ^b   Wittman, Vaughan ^a  

^a SANOFI PASTEUR   (France)

^b CureVac GmbH   (Germany)

Author keywords

Adjuvant; CLRs; Human; In vitro; Innate; MIMIC; Mouse; MRNA; RLRs; Self adjuvantation; TLRs; Vaccine

Indexed keywords

CHEMOKINE; CYTOKINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; MESSENGER RNA VACCINE; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; MESSENGER RNA;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL MATURATION; CLEC2D GENE; CLEC4GP1 GENE; CLEDL1 GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DDX58 GENE; FLOW CYTOMETRY; GENE; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IFIH1 GENE; IMMUNOCOMPETENT CELL; IMMUNOPHARMACOLOGY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A VIRUS (H1N1); INNATE IMMUNITY; MICROARRAY ANALYSIS; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; SPECIES COMPARISON; TLR3 GENE; TLR7 GENE; TLR8 GENE; TRANSLATIONAL RESEARCH; ANIMAL; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; GENE REGULATORY NETWORK; GENETICS; IMMUNOLOGY; LYMPH NODE; METABOLISM; NUCLEOTIDE SEQUENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BASE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC ENGINEERING; HUMANS; IMMUNITY, INNATE; INFLUENZA VACCINES; LYMPH NODES; MICE, INBRED C57BL; RNA, MESSENGER; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85010219814     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-1111-6     Document Type: Article

References (57)

1. Mastelic B, Garcon N, Del Giudice G, Golding H, Gruber M, Neels P, et al. Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biologicals. 2013;41:458-68.
2. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731-8.
3. Schroder K, Irvine KM, Taylor MS, Bokil NJ, Le Cao KA, Masterman KA, et al. Conservation and divergence in toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proc Natl Acad Sci USA. 2012;109:944-53.
4. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2013;110:3507-12.
5. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381:1021-8.
6. Takao K, Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2015;112(4):1167-72.
7. Davis MM. A prescription for human immunology. Immunity. 2008;29:835-8.
8. Germain RN. Vaccines and the future of human immunology. Immunity. 2010;33:441-50.
9. Morton JJ, Bird G, Refaeli Y, Jimeno A. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. Cancer Res. 2016;76:6153-8.
10. Smith DJ, Lin LJ, Moon H, Pham AT, Wang X, Liu S, Ji S, Rezek V, Shimizu S, Ruiz M, Lam J, Janzen DM, Memarzadeh S, Kohn DB, Zack J, Kitchen SG, An DS, Yang L. Propagating humanized BLT mice for the study of human immunology and immunotherapy. Stem Cells Dev. 2016;25:1863-73.
11. Higbee RG, Byers AM, Dhir V, Drake D, Fahlenkamp HG, Gangur J, et al. An immunologic model for rapid vaccine assessment-a clinical trial in a test tube. Altern Lab Anim. 2009;37(Suppl 1):19-27.
12. Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, Mistry Y, et al. International validation of novel pyrogen tests based on human monocytoid cells. J Immunol Methods. 2005;298:161-73.
13. Ma Y, Poisson L, Sanchez-Schmitz G, Pawar S, Qu C, Randolph GJ, et al. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model. Immunology. 2010;130:374-87.
14. Schindler S, Spreitzer I, Loschner B, Hoffmann S, Hennes K, Halder M, et al. International validation of pyrogen tests based on cryopreserved human primary blood cells. J Immunol Methods. 2006;316:42-51.
15. Zaitseva M, Romantseva T, Blinova K, Beren J, Sirota L, Drane D, et al. Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo. Vaccine. 2012;30:4859-65.
16. Drake DR III, Singh I, Nguyen MN, Kachurin A, Wittman V, Parkhill R, Kachurina O, Moser JM, Burdin N, Moreau M, Mistretta N, Byers AM, Dhir V, Tapia TM, Vernhes C, Gangur J, Kamala T, Swaminathan N, Warren WL. In vitro biomimetic model of the human immune system for predictive vaccine assessments. Disruptive Sci Technol. 2012;1:28-40.
17. Luna E, Agrawal P, Mehta R, Vernhes C, Viskov C, Amiral J, et al. Evaluation of immunostimulatory potential of branded and US-generic enoxaparins in an in vitro human immune system model. Clin Appl Thromb Hemost. 2015;21:211-22.
18. Miranda-Garcia M, Daebritz J, Varga G, Weinhage T, Ehrchen J, Barczyk K, et al. PW03-031-activation-induced cell death of human monocytes. Pediatr Rheumatol. 2013;11:A257.
19. Chen M, Wang J. Programmed cell death of dendritic cells in immune regulation. Immunol Rev. 2010;236:11-27.
20. Germain RN, Meier-Schellersheim M, Nita-Lazar A, Fraser ID. Systems biology in immunology: a computational modeling perspective. Annu Rev Immunol. 2011;29:527-85.
21. Mastelic B, Lewis DJ, Golding H, Gust I, Sheets R, Lambert PH. Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety. Biologicals. 2013;41:115-24.
22. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity. 2010;33:516-29.
23. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. 2014;15:195-204.
24. Gaucher D. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205:3119-31.
25. Querec TD. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2008;10:116-25.
26. Jones TR, Obaldia N III, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 1999;17:3065-71.
27. McCluskie MJ, Davis HL. Oral, intrarectal, and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 2000;19:413-22.
28. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000;19:950-7.
29. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol. 2002;168:1659-63.
30. Medzhitov R, Preston Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394-7.
31. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-9.
32. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21:317-37.
33. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174:1259-68.
34. Yoneyama M, Fujita T. Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity. 2008;29:178-81.
35. Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol. 2011;31:89-98.
36. O'Mahony DS, Pham U, Iyer R, Hawn TR, Liles WC. Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages. Int J Med Sci. 2008;5:1-8.
37. Reddy M, Eirikis E, Davis C, Davis HM, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods. 2004;293:127-42.
38. Rintahaka J, Wiik D, Kovanen PE, Alenius H, Matikainen S. Cytosolic antiviral RNA recognition pathway activates caspases 1 and 3. J Immunol. 2008;180:1749-57.
39. Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam TC, Verdurmen WP, et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol. 2011;8:627-36.
40. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012;9:1319-30.
41. Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med. 2012;14:428-39.
42. Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive((R)) vaccines. Hum Vaccines Immunother. 2013;9:2263-76.
43. Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34:1-15.
44. Sebastian M, Von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, et al. Messenger RNA vaccination in NSCLC: findings from a phase I/IIa clinical trial. J Clin Oncol 2011;29.
45. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30:1210-6.
46. Hoerr I, Obst R, Rammensee H, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30:1-7.
47. Schanen BC, Drake DR 3rd. A novel approach for the generation of human dendritic cells from blood monocytes in the absence of exogenous factors. J Immunol Methods. 2008;335:53-64.
48. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307-15.
49. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
50. Smyth GK. Limma: linear models for microarray data. In: Gentlemen R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using r and bioconductor. New York: Springer; 2005. p. 397-420.
51. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067-75.
52. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
53. Caron G, Duluc D, Fremaux I, Jeannin P, David C, Gascan H, Delneste Y. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol. 2005;175:1551-7.
54. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R, Kastelein RA. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004;172:2225-31.
55. Pot C, Apetoh L, Awasthi A, Kuchroo VK. Molecular pathways in the induction of interleukin-27-driven regulatory type 1 cells. J Interferon Cytokine Res. 2010;30:381-8.
56. Douagi I, Gujer C, Sundling C, Adams WC, Smed-Sorensen A, Seder RA, et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol. 2009;182:1991-2001.
57. Smyth C, Logan G, Weinberger RP, Rowe PB, Alexander IE, Smythe JA. Identification of a dynamic intracellular reservoir of cd86 protein in monocytes that is not associated with the golgi complex. J Immunol. 1998;160:5390-6.